

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanxi Central Pharmaceutical International Limited

正中藥業國際有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 327)

ANNOUNCEMENT

On 21 September 2004, the Company received a petition to the High Court from the solicitors acting for DBS Bank (Hong Kong) Limited (formerly known as Dao Heng Bank Limited), a judgement creditor of the Company, for the winding up of the Company. The judgement debt due by the Company to the judgement creditor is HK\$32,407,611.97.

The petition will be heard on 20 October 2004 at High Court.

The Company is in the course of preparing a proposal for the resumption of trading of the Company's shares on the stock exchange. If there will be a chance of success, the Company will negotiate with the judgement creditor and other creditors for a settlement. Otherwise, owing to lack of funds, the Company is unable to proceed with the negotiation.

Trading of the shares of the Company remains suspended until further notice.

As at the date of this announcement, the board of the Company is comprised of two executive directors, Mr. SUN Ying Chung and Mr. HUNG Shui Nam, and two independent non-executive directors, Dr. KO Siu Shing, Patrick and Mr. SIUw Ling, Robert.

By Order of the Board
Shanxi Central Pharmaceutical International Limited
Hung Shui Nam
Director

Hong Kong, 28 September 2004

* *for identification only*

Please also refer to the published version of this announcement in The Standard.